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Abstract
Introduction: The receptor for advanced glycation end products (RAGE) has been considered as one of the major
pattern recognition receptors and plays an important role in the development of sepsis and multiple organ
dysfunction in critical illnesses. Although genetic variants of the RAGE gene have been shown to be well associated
with susceptibility to some inflammatory diseases, little is known about their clinical relevance in the development
of sepsis in critical ill patients.
Methods: Four genetic variants were selected from the entire RAGE gene and genotyped using pyrosequencing
and polymerase chain reaction-length polymorphism methods. Association studies were performed in two
independent Chinese Han populations.
Results: Among the four genetic variants, only the rs1800625 polymorphism was significantly associated with
sepsis morbidity rate and multiple organ dysfunction (MOD) scores in patients with major trauma both in
Chongqing (n = 496) and Zhejiang (n = 232) districts, respectively. Results from ex vivo responsiveness of peripheral
blood leukocytes indicated that the rs1800625 polymorphism was well associated with decreased production of
TNFa. In addition, the rs1800625 polymorphism could significantly inhibit the promoter activities of the RAGE gene.
Conclusions: The rs1800625 polymorphism is a functional variant, which might be used as a relevant risk estimate
for the development of sepsis and multiple organ dysfunction syndrome in patients with major trauma.
Introduction
The receptor for advanced glycation end products (RAGE),
not only limiting to mediation of advanced glycation end
products (AGEs), has been recognized as a multiligand
receptor, especially playing pivotal roles in innate immune
responses as a pattern-recognition receptor (PRR) in sen-
sing both pathogen-associated molecular patterns
(PAMPs) and endogenous damage-associated molecular
patterns (DAMPs) [1-6]. RAGE could up-regulate the
capacity of leukocytes to kill bacteria [2] and facilitates
host defense during bacterial infection [3,4]. Besides its
anti-microbial effects, RAGE also acts as an endothelial
adhesion receptor for leukocyte integrins and promotes
leukocyte recruitment [5]. Engagement of RAGE by its
diverse ligands, such as lipopolysaccharides, high-mobility
group box 1 protein, AGEs, results in receptor-dependent
signaling and amplification of pro-inflammatory responses
[1]. RAGE is up-regulated at levels of both mRNA and
protein in sepsis [6]. Administration of AGE-modified pro-
tein has the potential to activate RAGE/NF-kB-mediated
inflammatory reactions, causing increased mortality in
experimental peritonitis [7]. In addition, the genomic dele-
tion of RAGE [8,9], or inhibition of RAGE signaling [8,10]
results in markedly decreased septic response and signifi-
cantly increased survival rates in a mouse model of sepsis.
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Therefore, RAGE has been considered to be one of the
major PRRs responsible for the development of sepsis [11]
and its subsequent organ dysfunction [12-14]. It might be
used as a potential molecular marker and therapeutic
target for sepsis [15-17].
The RAGE gene is located on chromosome 6p21.3 in the
major histocompatibility complex (MHC) locus in the
class III region [18]. Growing evidence indicates that allelic
variation within the key domains of RAGE gene may influ-
ence the magnitude of proinflammatory response, thereby
affecting susceptibility to acute and chronic inflammatory
diseases [19]. A total of 97 genetic variants have been
identified so far in the entire RAGE gene. However, only
three of them (rs1800625, rs1800624 and rs2070600) have
been well studied in relation to their clinical relevance.
The rs1800625 is revealed in association with increased
risk for diabetes [20], diabetic retinopathy [21] and color-
ectal cancer [22]. The rs1800624 polymorphism was
shown to be associated with increased susceptibility to
Crohn’s disease [23], coronary artery disease [24], in-stent
restenosis after coronary stent implantation [25], ischemic
heart disease [26], and myocardial infarction [27]. The
rs2070600 polymorphism revealed increased risk of rheu-
matoid arthritis [28], multiple sclerosis [29] and coronary
artery disease in non-diabetics [30]. In spite of the above
findings, there also have been plenty of controversial
reports with respect to the clinical relevance of the above
three gene polymorphisms [26,27,29,31-36]. In addition,
other polymorphisms, such as 2184A/G, 2245G/A,
rs17493811 and rs9469089, also have been reported in
relation to diabetes [37-39]. However, little is known
about the clinical relevance of the genetic variants of
RAGE gene in relation to the development of sepsis and
multiple organ dysfunction syndrome (MODS).
To comprehensively assess the clinical relevance of the
common genetic variants within the entire RAGE gene,
haplotype bins were constructed to identify haplotype tag-
ging single nucleotide polymorphisms (SNPs) (htSNPs)
within the entire RAGE gene and its surrounding regions.
In view of that, the majority of trauma patients are young
people with little history of pre-existing diseases [40]. The
trauma patient cohort is appropriate to investigate the
association of genetic factors with susceptibility or resis-
tance to sepsis in critically ill patients. Four genetic var-
iants were selected, and two independent Chinese Han
populations were recruited in this study cohort. The
rs1800625 polymorphism (-429T/C) was demonstrated to
be clinically relevant and have functional activity.
Materials and methods
Study population and clinical evaluation
A total of 728 unrelated patients with major trauma
recruited in this study were Han Chinese and from
Chongqing in south-western China (n = 496) and
Zhejiang in eastern China (n = 232), respectively. The
trauma patients were admitted to the Department of
Trauma Surgery in the Daping Hospital and the Chongq-
ing Emergency Medical Center between 1 January 2005
and 1 May 2011, and to the Department of Trauma and
Emergency in the Second Affiliated Hospital, Zhejiang
University between 1 January 2008 and 1 May 2011.
They were enrolled in the study if they met the following
inclusion criteria: 1) were between 18 and 65 years of
age, 2) expected an Injury Severity Score (ISS) greater
than 16 combined with the presence of at least one life
threatening injury and at least one additional severe
injury in another part of the body, and 3) had a probabil-
ity of survival greater than 48 h. Patients were not eligible
if they had penetrating injuries or preexisting cardiovas-
cular, respiratory, renal, hepatic, hematologic or immu-
nologic diseases. ISS was performed according to the
abbreviated injury scale by independent evaluators [41].
Standard demographic, laboratory and clinical data were
extracted from a prospectively collected database. The
protocol was approved by the Ethical and Protocol
Review Committee of the Third Military Medical Univer-
sity, and informed consent was obtained from the
patients and the patients’ next of kin. Patient confidenti-
ality was preserved according to the guidelines for studies
of human subjects.
The patients with major trauma were prospectively
monitored after admission by physicians who did not
know the genotypes. The definitions of sepsis and
infection were shown in Additional file 1. Daily physio-
logic and laboratory data were collected during the
ICU stay and clinical events were recorded thereafter,
until death or hospital discharge. Multiple organ dys-
function scores were calculated as the sum of the
simultaneously obtained individual organ scores on
each hospital day [42]. Neurological scoring was not
performed because every patient was sedated. MODS is
defined as a Marshall score of 4 or more for at least
two consecutive days based on the comparative studies
reported by A Sauaia [43].
Tag SNP selection
The human RAGE gene (Accession Number:
NC_000006) was pinpointed to chromosome 6, position
32148745-32152022 (data retrieved from Genbank in
the website of NCBI). The RAGE 5’ flanking region
from -505 in a 5’direction has been shown to overlap
with PBX2, a gene that has a pseudogene copy on chro-
mosome 3, which might make any studies of poly-
morphisms in this duplicated region potentially fraught
with error [44]. Therefore, besides all exons and introns
of the RAGE gene, 505-bp upstream of the transcription
start site and 5,000-bp downstream of the stop codon
were included (8.872 kb total).
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Genetic variation data for the entire RAGE gene and its
surrounding selected regions were obtained from the
healthy Chinese Han Beijing (CHB) population of
HapMap. From this database, a total of 11 SNPs have
been identified in the CHB population (Table 1). Ten of
them were common SNPs with a minor allele frequency
(MAF) more than or equal to 0.05, which were then
selected for the analysis of htSNPs (Figure 1). Haplotype
blocks (bins) were constructed using LDselect (Christo-
pher S. Carlson and Deborah A. Nickerson, Seattle,
Washington, USA), a software package that provides
computation of linkage disequilibrium (LD) statistics and
population haplotype patterns from genotype data [45].
This algorithm selects a subset of htSNPs that efficiently
describe all common patterns of variants in a gene, based
on two primary criteria: 1) the MAF is more than or
equal to 0.05 and 2) the minimum level of association
between assayed and unassayed SNPs, measured by the
linkage disequilibrium statistic r2 is more than or equal
to 0.8. Given these parameters, LDSelect selects a subset
of htSNPs that captures all known common genetic
variants within the entire gene.
To determine the possible functionality of the htSNPs
selected from the 5’-flanking region of the RAGE gene,
on-line software was used to analyze the effect of these
SNPs on potential transcription factor binding sites.
Genotyping
Blood specimens were collected in tripotassium ethylene-
diamine tetraacetic acid sterile tubes from trauma patients
immediately after admission to avoid the effect of blood
transfusion. The genomic DNA was isolated from whole
blood using the Wizard genomic DNA purification kit
(Promega, Madison, WI, USA) according to the manufac-
turer’s protocol. Pyrosequencing was used for genotyping
of rs1800625, rs1800624 and rs2070600 polymorphisms
according to our previous reports [46]. Polymerase chain
reaction (PCR) - length polymorphism (LP) approach was
used for genotyping of the 63 bp ins/del variant. The PCR
primers and the annealing temperature were shown in
Additional file 2, Table S1. Genotyping was performed in
a blinded fashion without knowledge of the patients’ clini-
cal data, and approximately 10% of the samples were gen-
otyped in duplicate to monitor genotyping quality.
Ex vivo tumor necrosis factora production
A human whole-blood assay was used as in our previous
method. In brief, aliquots of whole blood collected from
the trauma patients immediately after admission were
mixed 1:1 with Roswell Park Memorial Institute (RPMI)
1640 culture medium (Thermo Scientific, Beijing, China),
and incubated with 100 ng/ml LPS (Escherichia coli O26:
B6, Difco Laboratories, Detroit, MI, USA) in a sample
mixer at 37°C for 4 h. After centrifugation, the superna-
tants were aspirated and aliquoted for stoRAGE at -80°C.
Tumor necrosis factor-alpha (TNF-a) in the supernatants
was assayed with a sandwich enzyme linked immunosor-
bent assay (ELISA), according to the manufacturer’s
instructions (Endogen, Woburn, MA, USA). The detection
limits of the assay were 4 pg/ml.
Functionality of the rs1800625 polymorphism
The possible effect of rs1800625, which is located in the
5’-flanking region (-429T/C), on the promoter activity was
investigated using a reporter gene assay system [47]. A
531-bp sequence (-504 approximately +26) of the RAGE
gene containing T or C allele at position -429 were
obtained according to the method described in Additional
file 3 and were directly inserted into a promoterless pGL3-
Basic vector (Promega, Madison, WI, USA) containing the
firefly luciferase gene as a reporter. Human U937 were
cultured in RPMI 1640 medium (Hyclone, Logan, UT,
USA) containing 10% fetal calf serum, 3 mM glutamine,
penicillin-streptomycin (100 U/mL for each), and 23 mM
sodium bicarbonate at 37°C in a humidified 5% CO2 air
atmosphere. After incubation for 24 hours, the cultured
cells were co-transfected with 0.8 μg of the constructed
vectors or pGL3-Basic original plasmid and 20 ng control
Renilla luciferase reporter plasmid pRL-CMV using Lipo-
fectmine 2000 system (Invitrogen, Carlsbad, CA, USA). At
24 hours post-transfection, the cells were treated with LPS
(100 ng/mL) for 24 hours. Then luciferase activity of the
transfected cells was measured using the Luciferase Assay
System (Promega) following the supplier’s protocol on a
Luminoskan Ascent luminometer (Thermo Labsystems,
Helsinki, Finland). Transfection efficiency was normalized
by measuring the luciferase activity of control plasmid
pRL-CMV. Luminescence experiments were performed in
triplicate with each transfection. Three independent trans-
fections were performed for each constructed vector.
Results are expressed as fold increase in relative luciferase
Table 1 SNPs identified within whole RAGE gene
NO. rs number Location Variation MAF Region
1 rs1800625 -429 T/C 0.122 promoter
2 rs1800624 -374 T/A 0.163 promoter
3 rs3131300 79 A/G 0.122 Intron1
4 rs2070600 570 G/A 0.289 Exon3
5 rs2269422 719 A/G 0.057 Intron3
6 rs1035798 791 C/T 0.167 Intron3
7 rs184003 1717 G/T 0.116 Intron5
8 rs3134940 2197 A/G 0.11 Intron7
9 rs2853807 2441 C/T 0.068 Intron7
10 rs2071288 2753 G/A 0.022 Intron8
11 rs8365 3610 C/G 0.114 3’-flanking
Genetic variation data for the entire RAGE gene was obtained from the
HapMap project for 45 members of the Chinese Han Beijing (CHB) population.
MAF, minor allele frequency; SNPs, single nucleotide polymorphisms
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activity of the RAGE promoter construct vectors com-
pared with the relative luciferase activity of pGL3-Basic.
Statistical analysis
Sample size was calculated using online Power and Sample
Size Program software (William D Dupont and Walton D
Plummer, Nashville, Tennessee, USA) [48]. The desired
power of our study was set at 80% with a significance level
of 0.05 in a two-sided test. We chose the log-additive
inheritance model, which is the most suitable for polygenic
diseases.
Allele frequencies for each SNP were determined by
gene counting. Genotype distribution of each SNP was
tested for departure from Hardy-Weinberg equilibrium
(HWE) using c2 analyses. The extent of pair-wise linkage
disequilibrium between polymorphisms was determined
by the Haploview (version 4.0) software (Jeffrey C Barrett
and Mark J Daly, Cambridge, MA, USA). The association
between polymorphisms and supernatant TNFa was
determined using one-way analysis of variance. The asso-
ciation between polymorphisms and MOD scores was
performed using analysis of one-way ANOVA testing
with age, sex ratio and injury severity to adjust for possi-
ble confounding effects. Three genetic models (dominant,
recessive and allele-dose effects) were used. The associa-
tion of genotypes with sepsis morbidity rate was deter-
mined by c2 analysis. Odds ratios with 95% confidence
intervals were calculated by multiple logistic regression
analyses to estimate the relative risk of sepsis. Age, sex
ratio and injury severity were used as covariances of mul-
tiple logistic regression. P-values smaller than 0.05 after
Bonferroni correction for multiple testing were consid-
ered significant. All statistic analysis was carried out
using SPSS Version 13.0.
Results
Construction of haplotype bins and selection of htSNPs
There are a total of 10 SNPs with a minor allele frequency
of more than or equal to 5% in the CHB population,
which constructed two haplotype bins (Figure 1). Based on
the analysis of tagging threshold of r2 of SNPs in each bin,
one htSNP was selected from each bin for genotyping. In
combination with previous association studies [21], the
rs1800625 and rs1800624 polymorphisms were selected as
htSNP of the respective bins (Figure 1). The rs2070600
polymorphism, though not forming any bin with other
SNPs, was still selected due to its nonsynonymous varia-
tion, showing a substitution of the conserved glycine to
serine at amino acid 82 (Gly82Ser) [19]. In addition, a
deletion variant (63 bp ins/del) was identified in the region
of 5’-flanking region (-407 to -345). This variant, although
not being included in the current public gene polymorph-
ism database, was shown to affect the promoter activities
of the RAGE gene [21]. As a result, this variant was also
selected in this study cohort.
Overall clinical characteristics of patients with major
trauma
There were two independent patient cohorts, consisting of
496 and 232 individuals, respectively. All patients survived
at least 48 hours after admission and completed genotyp-
ing. Baseline data of the patients are shown in Table 2.
Patients were severely injured and mostly young. Sepsis
morbidity rate was 40.7% and 37.9%, respectively in the
Chongqing and Zhejiang cohorts. No pathogens were
identified in blood cultures in 53.0% and 50.0% of the
patients in both cohorts as the causative microorganism
for sepsis, although they had an identified site of infection.
The common pathogens identified in this study cohort
Figure 1 Overview of selected tSNPs within the entire RAGE gene. (A) The pair-wise analysis of linkage disequilibrium (LD), based on r2,
among the 10 SNPs with a minor allele frequency ³5% within the RAGE gene and 505 bp up- and 5,000 bp down-stream regions. The selected
tSNPs are indicated by trigones. A LD-plot of the 10 SNPs is displayed by using r2-black and white color scheme. Black represents very high LD
(r2 = 0.8-1), and white indicates the absence of correlation (r2 = 0-0.2) between SNPs. (B) The two tSNPs and SNPs that are indirectly measured
by them are listed with corresponding r2-values. Major and minor alleles of the selected tSNPs are given with their frequencies, based on the
HapMap data for the CHB population.
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were Staphylococcus aureus, coagulase-negative staphylo-
cocci, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa, Escherichia coli, Enterococcus
spp. and Enterobacter cloacae. Gram negative infection
accounted for about 21% and 24.6%, Gram positive infec-
tion for about 18% and 15.9%, and mixed infection for
about 5.8% and 7.3%, respectively, in the Chongqing and
Zhejiang cohorts. Median time point for sepsis occurrence
in the whole study cohort was 6.0 days (interquartile range
5.0 to 9.0 days. Chongqing: median 7.0 days, interquartile
range 5.0 to 8.0 days; Zhejiang: median 6.0 days, interquar-
tile range 5.0 to 7.0 days). Organ dysfunction occurred in
72.1% and 73.2% of the patients in both cohorts, among
whom 213 (42.9%) and 96 (41.4%), respectively, had two
or more organ dysfunctions. Among the patients with
MODS, those with sepsis accounted for 40.7% and 37.9%
in Chongqing and Zhejiang populations, respectively.
Among the patients with sepsis, the median time point for
MODS occurrence was shown to be 8.0 days (interquartile
range 6.5 to 10.5 days) in Chongqing, and 9.0 days (inter-
quartile range 7.0 to 11.0 days) in Zhejiang patients,
respectively. With respect to the patients without sepsis,
the median time point for MODS occurrence was 5.0 days
(interquartile range 4.0 to 8.0 days) in Chongqing, and
5.5 days (interquartile range 3.5 to 7.5 days) in Zhejiang
patients, respectively.
Allele frequencies and genotype distribution
The MAF of the rs2070600, rs1800624 and rs1800625
polymorphisms among the trauma patients were similar to
those among the CHB population in the HapMap database
(Table 3). The MAF of the 63 bp ins/del variant was 7.7%
and 6.3% in the Chongqing and Zhejiang districts, respec-
tively. This seems to be higher in the Chinese Han popula-
tion when compared with that in Western populations,
among whom the MAF of the 63 bp ins/del variant is less
Table 2 Overall clinical characteristics of patients with major trauma
Chongqing (N = 496) Zhejiang (N = 232)
Age (yrs) 40.4 ± 14.2 (18 to 65) 41.0 ± 13.1 (18 to 65)
Male/female, n 395/101 190/42
Injured body regions, n (%)
Head, n 187 (37.7) 73 (31.5)
Thorax, n 205 (41.3) 142 (61.2)
Abdomen, n 136 (27.4) 74 (31.9)
Extremities, n 252 (50.8) 165 (71.1)
Number of regions injured, n (%)
One, n 145 (29.2) 74(31.9)
Two, n 133 (26.8) 59 (25.4)
Three or above, n 80 (16.1) 37 (15.9)
ISS 22.0 ± 10.5 23.3 ± 8.7
≥16, <25, n (%) 301 (60.7) 131 (56.5)
≥25, n (%) 195 (39.3) 101 (43.5)
Organ dysfunction, n (%)
One, n 132 (26.6) 76 (32.8)
Two, n 125 (25.2) 59 (25.4)
Three or above, n 72 (14.5) 35 (15.1)
Sepsis, n (%) 202 (40.7) 88 (37.9)
Source of infection, %
Respiratory tract infection 41.6 39.8
Primary bloodstream infection 21.8 23.9
Urinary tract infection 16.3 11.4
Catheter associated infection 10.9 9.1
Wound infection 7.4 9.1
Others* 2.0 6.8




Mixed Gram negative and positive 5.8 7.3
Negative blood cultures 53.0 50.0
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than 1% [21]. The genotype distribution of the four genetic
variants was in agreement with the Hardy-Weinberg equi-
librium (P >0.05, Table 3), indicating that both allele and
genotype frequencies of these variants in the population
remain constant; that is, they are in equilibrium from gen-
eration to generation.
Clinical relevance of the four genetic variants in trauma
patients in the Chongqing district
We first selected 496 Chinese Han patients with major
trauma in the Chongqing district to investigate the clini-
cal relevance of the four variants (63 bp ins/del,
rs2070600, rs1800624 and rs1800625) of the RAGE
gene. As shown in Table 4, there were no significant dif-
ferences in age, gender ratio and ISS among patients
stratified according to the different genotypes of each
variant. Among the four genetic variants selected in this
study, only the rs1800625 was shown to be significantly
associated with the risk for development of sepsis and
MODS in major trauma patients. The patients carrying
the variant C allele revealed a significantly lower sepsis
morbidity rate and MOD scores, when compared with
those carrying the T allele (P = 0.003 for sepsis morbid-
ity rate and P = 0.015 for MOD scores in case of domi-
nant effect, P = 0.032 for MOD scores in case of
recessive effect). Data from regression analyses further
indicated that the association of this polymorphism was
in significant allele-dose effect with sepsis morbidity rate
(OR = 0.428, 95% CI: 0.276 to 0.886, P = 0.026), and
MOD scores (P = 0.045), respectively. There were no
significant differences in the sepsis morbidity rate and
MOD scores among different groups when patients
were stratified according to the genotypes of the other
three genetic variants.
The clinical relevance of the four variants in trauma
patients in the Zhejiang district
In order to confirm the biological significance of the four
genetic variants selected in this study, we further investi-
gated their clinical relevance in another Chinese Han
population of trauma patients, who lived in the Zhejiang
province of eastern China. As expected, only rs1800625
was shown to be significantly associated with risk of sep-
sis and MODS in trauma patients in the Zhejiang district.
The sepsis morbidity rates and MOD scores were signifi-
cantly lower in the patients carrying the variant C allele
compared with those carrying the T allele (P = 0.016 and
P = 0.042 for sepsis morbidity rates and MOD scores in
case of dominant effect, Table 4). Data from linear
regression analysis revealed that the association of this
polymorphism was in borderline significant allele-dose
effect with MOD scores (P = 0.048).
Effect of rs1800625 on LPS-induced TNF-a production
As shown in Figure 2, the rs1800625 polymorphism was
well associated with the LPS responsiveness of peripheral
blood leukocytes. LPS-induced TNF-a production was sig-
nificantly lower in patients with the variant C allele than
that in those with wild T allele (CC genotype: 5423.4 ±
2059.4 pg/ml, TC genotype: 5763.1 ± 2771.8 pg/ml and
TT genotype: 6146.7 ± 3978.4 pg/ml, P = 0.017 for domi-
nant effect).
Effect of the rs1800625 on promoter activity
In view of the location of the rs1800625 in the 5’-flanking
region of the RAGE gene, we further hypothesized that
the T®C variation of this polymorphism might affect the
promoter activities of the RAGE gene. Figure 3 showed
that the fold increase of relative luciferase activity (RLA)
was significantly lower in cells transfected with variant C
allele than those transfected with wild T allele (1.36 ±
0.11 vs. 1.57 ± 0.27, P = 0.032).
Discussion
It has been demonstrated that inappropriate immune
inflammatory response contributes to the development of
sepsis and MODS in critically ill patients [40]. Increasing
evidence suggests that genetic variants, particularly single
nucleotide polymorphisms (SNPs), are critical determi-
nants for inter-individual differences in both inflammatory
responses and clinical outcome [48,49]. Delineating the
variation in genes and associated differences in immune
Table 3 Distribution of the four variants in the RAGE gene among trauma patients
MA (%) Genotypes, n (%) HWE
SNPs N Patients Databank wild Heterozygous variant P-values
Chongqing 63bp ins/del 496 7.7 423 (85.3) 70 (14.1) 3 (0.6) 0.96
rs2070600 496 29.4 28.9 247 (49.8) 206 (41.5) 43 (8.7) 0.99
rs1800624 496 14.8 16.3 364 (73.4) 117 (23.6) 15 (3.0) 0.14
rs1800625 496 14.7 12.2 365 (73.6) 116 (23.4) 15 (3.0) 0.128
Zhejiang 63bp ins/del 232 6.3 203 (87.5) 29 (12.5) 0 (0) 0.31
rs2070600 232 27.4 28.9 126 (54.3) 85 (36.6) 21 (9.1) 0.23
rs1800624 232 11.6 16.3 181 (78.0) 48 (20.7) 3 (1.3) 0.93
rs1800625 232 15.9 12.2 163 (70.3) 64 (27.6) 5 (2.2) 0.66
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Table 4 Clinical relevance of four variants among trauma patients
Polymorphic sites Genotypes N Age (yr) Sex (M/F) ISS Sepsis, n/% MOD score
Chongqing ins/ins 423 40.2 ± 14.6 334/89 22.3 ± 10.5 178 (42.1) 6.4 ± 2.4
63 bp ins/del ins/del 70 40.9 ± 11.1 59/11 20.5 ± 10.5 23 (32.9) 6.1 ± 2.8
del/del 3 47.3 ± 18.8 2/1 24.3 ± 8.5 1 (33.3) 6.0 ± 1.7
GG 247 39.5 ± 14.4 198/49 22.2 ± 11.4 100 (40.5) 6.7 ± 2.6
rs2070600 GA 206 41.0 ± 14.4 161/45 21.9 ± 9.4 84 (40.8) 6.1 ± 2.3
AA 43 42.5 ± 11.5 36/7 22.0 ± 10.4 18 (41.9) 5.7 ± 1.6
TT 364 40.4 ± 14.3 291/73 22.2 ± 10.4 148 (40.7) 6.3 ± 2.4
rs1800624 TA 117 40.5 ± 14.3 91/26 21.7 ± 11.0 51 (43.6) 6.5 ± 2.5
AA 15 39.7 ± 12.0 13/2 20.2 ± 8.8 3 (20.0) 7.0 ± 2.6
TT 365 40.0 ± 14.1 291/74 22.4 ± 10.5 163 (44.7) 6.9 ± 2.4
rs1800625 TC 116 42.4 ± 14.4 89/27 21.3 ± 10.7 35 (30.2) 6.0 ± 2.2
CC 15 37.3 ± 9.9 15/0 17.2 ± 9.8 4 (26.7) 5.3 ± 1.5
a1 a2, b1, c1
Zhejiang ins/ins 203 41.0 ± 12.9 165/38 23.3 ± 8.6 74 (36.4) 6.9 ± 3.4
63bp ins/del ins/del 29 41.1 ± 14.9 25/4 22.7 ± 9.3 14 (48.3) 8.4 ± 3.0
del/del 0 - - - 0 (0) -
GG 126 41.3 ± 13.4 102/24 22.7 ± 8.6 48 (38.1) 7.1 ± 3.1
rs2070600 GA 85 40.7 ± 12.4 70/15 23.0 ± 8.5 35 (41.2) 6.9 ± 3.6
AA 21 40.6 ± 14.5 18/3 27.5 ± 8.6 5 (23.8) 6.9 ± 2.8
rs1800624 TT 181 41.0 ± 13.3 150/31 23.4 ± 8.7 70 (38.7.) 7.0 ± 3.5
TA 48 40.6 ± 13.0 38/10 22.4 ± 8.3 16 (33.3) 7.4 ± 3.2
AA 3 44.7 ± 7.1 2/1 28.0 ± 14.1 2 (67.7) 6.7 ± 2.3
TT 163 41.4 ± 13.2 138/25 23.7 ± 8.5 70 (42.9) 7.3 ± 3.3
rs1800625 TC 64 40.9 ± 13.2 47/17 21.8 ± 8.6 16 (25.0) 6.9 ± 3.2
CC 5 37.7 ± 15.7 4/1 24.3 ± 12.0 2 (40.0) 6.3 ± 2.5
a3 a4, c2
A, dominant effect (variant homozygotes +heterozygotes vs. wild homozygotes) as analyzed by ANOVA, a1P = 0.003, a2P = 0.015, a3P = 0.016, a4P = 0.042; b,
recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes); as analyzed by ANOVA, b1P = 0.032; c, Allele Dose Effect as analyzed by linear
regression, c1P = 0.045, c2P = 0.048.
Figure 2 Effect of the rs1800625 (-429T/C) on LPS-induced
TNF-a production. One-way ANOVA was used to assess statistical
significance. *P = 0.017 for dominant association (TT + TC vs. TT).
Figure 3 Effect of the -429T/C polymorphism on the
transcription activity of the RAGE promoter. Relative luciferase
activity (RLA) was measured in U937 cells transfected with -429T or
-429C plasmid constructs as described in methods. The fold increase
of RLA was significantly lower in cells transfected with variant C
allele than those transfected with wild T allele (P = 0.032).
Zeng et al. Critical Care 2012, 16:R131
http://ccforum.com/content/16/4/R131
Page 7 of 11
inflammatory response might contribute to the develop-
ment of new genetically tailored diagnostic and therapeu-
tic interventions that will improve outcome in critically ill
patients. RAGE, a member of the immunoglobulin super-
family of cell surface molecules, was initially identified and
characterized as a cellular interaction site for AGEs [6].
Growing evidence has indicated that RAGE is an impor-
tant PRR, involved in amplification of pro-inflammatory
response and antimicrobial host defense [7]. The present
study, to our knowledge for the first time, investigated the
potential clinical relevance of the genetic variants identi-
fied within the entire RAGE gene in the Han Chinese
population. Three SNPs (rs1800625, rs1800624 and
rs2070600) are selected from 10 SNPs with a minor allele
frequency of more than or equal to 5% based on LD
threshold and their possible functionalities. The 63 bp ins/
del variant, although being rare in Western populations
with an MAF of less than 1% [21] and not being included
in the current public database of the Chinese Han popula-
tion, is shown to be a common polymorphism in the
Chinese Han population, showing 7.7% in Chongqing and
6.3% in Zhejiang populations, respectively, in our study
cohorts. Although the rs2070600 polymorphism occurs in
less than 5% in many populations, such as Brazilian and
Finnish populations, the MAF was approximately 20% in
Asia populations [50]. This is further confirmed in our
study cohorts, showing an MAF of 29.4% and 27.4% in the
Chongqing and Zhejiang districts. Therefore, the four
genetic variants selected in this study cohort are all com-
mon gene polymorphisms in the Chinese Han population.
Case-control study is a common and convenient asso-
ciation study design for finding a genetic basis of disease.
However, a major limitation in this approach is the
potential for population stratification when inappropriate
patient-control matching occurs, such as using healthy
blood donors as the control group in the study. To avoid
confounding association, we only selected trauma
patients and prospectively followed them to determine
whether those who had genetic variants had a lesser or
higher risk of post-traumatic MODS and sepsis. In addi-
tion, the patients recruited in this study cohort were all
Han Chinese. In the context of a biologically relevant
phenotype and a racially uniform population, this might
maximize the likelihood of finding a meaningful genetic
association. Furthermore, two independent patient popu-
lations from different geographic regions were used in
this study cohort. Our results indicate that among the
four genetic variants, only the rs1800625 polymorphism
reveals a strong clinical relevance, showing lower sepsis
morbidity rate and MOD scores in the patients with the
variant C allele both in Chongqing and Zhejiang cohorts.
This is in contrast to its association with other diseases,
showing increased risk of diabetes [18], diabetic
retinopathy [19] and colorectal cancer [20]. This might
be because RAGE plays different roles in the pathogenesis
of different diseases. The other three genetic variants
(rs1800624, rs2070600 and 63bp ins/del), being asso-
ciated with an increased risk of some inflammatory dis-
eases [18,26-28], are not shown to be associated with risk
of sepsis and MODS in patients with major trauma in the
Chongqing and Zhejiang cohorts. In combination with
previous reports showing that the rs1800625 polymorph-
ism is a common allele in other ethnic populations with
the minor allele frequency of more than 10% [51-53], it
might be used as a relevant risk estimate for sepsis and
MODS in critical ill patients.
Given the functional significance of the rs1800625
polymorphism, we further investigated the association of
this SNP with LPS-induced responsiveness of peripheral
leukocytes obtained from trauma patients. The whole
blood samples were taken immediately after admission in
an attempt to avoid the potential effects of blood transfu-
sion and fluid resuscitation. As we expected, the
rs1800625 polymorphism is significantly associated with
lower responsiveness of peripheral blood leukocytes in
response to LPS stimulation, showing much lower levels
of TNFa in patients carrying the variant C allele. This is
in accordance with the clinical association of the
rs1800625 with risk of sepsis and MODS in patients with
major trauma. The rs1800625 polymorphism is located
in the promoter region of the RAGE gene and induces
T®C substitution at position -429 [54]. Bioinformatics
analysis reveals that binding sites for some transcription
factors (GATA-1, GATA-2 and sp1) (motif.genome.jp/)
are present in close proximity to nucleotide -429 in the
promoter. In order to further determine the functionality
of the rs1800625 polymorphism, we investigated the
effect of the rs1800625 polymorphism on the RAGE pro-
moter activity using reporter gene assay system. Using
the U937 cell line, we show that the fold increase of RLA
is significantly lower in the cells transfected with vectors
containing -429 C allele. It suggests that T®C variation
at position -429 could significantly reduce the transcrip-
tional activity of the RAGE promoter. Taken together,
The T® C variation at position -429 might reduce DNA-
protein interaction, and then inhibit RAGE gene tran-
scription, which contributes to decreased TNF produc-
tion by peripheral blood leukocytes in response to ex vivo
LPS stimulation, leading to decreased risk of sepsis and
MODS in patients with major trauma.
There are some limitations to our current study. First,
the sample size of both patient groups recruited in this
study was relatively small, especially in the Zhejiang
cohort. The values of power for rs1800625 in the Zhejiang
cohort are shown to be 51.7% and 36.2% for sepsis mor-
bidity rate and MOD scores, respectively, at a significance
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of 0.05. The too small number size of patients with the
rs1800625 TC genotype (n = 5) and their higher incidence
of sepsis (40%) in the Zhejiang cohort might explain the
discrepancy in sepsis morbidity rate between the Chongq-
ing and Zhejiang cohorts. The clinical relevance of the
rs1800625 polymorphism needs to be validated in a larger
population. Second, the population we studied was only
Han Chinese who live in the Chongqing and Zhejiang dis-
tricts. Our results may not be generalized to other popula-
tions. Third, difficulties in obtaining additional blood
samples did not allow us to determine plasma sRAGE
levels, or RAGE expression on peripheral blood leuko-
cytes; therefore, the in vivo association between the
rs1800625 polymorphism and RAGE activities needs to be
confirmed. Despite the limited power of the clinical asso-
ciation study, our results demonstrate that the rs1800625
polymorphism might be a causal risk allele for sepsis and
MODS in patients with major trauma
Conclusions
The present study investigated the clinical relevance of the
genetic variations within the entire RAGE gene by means
of construction of haplotype bins in patients with major
trauma. We demonstrate that rs1800625 polymorphism is
shown to affect TNFa production, and might be used as a
relevant risk estimate for sepsis and MODS in trauma
patients. In addition, the rs1800625 polymorphism could
significantly enhance the promoter activities of the RAGE
gene.
Key messages
• Among the four tagSNPs of RAGE, only rs1800625
reveals a strong clinical relevance, showing lower sepsis
morbidity rate and MOD scores in the patients with the
variant C allele in both the Chongqing and Zhejiang
cohorts.
• The rs1800625 polymorphism is significantly asso-
ciated with lower responsiveness of peripheral blood
leukocytes in response to LPS stimulation, showing
much lower levels of TNFa in patients carrying the var-
iant C allele.
• The rs1800625 polymorphism could significantly
enhance the promoter activities of the RAGE gene.
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